Document |
Document Title |
WO/1997/006133A1 |
Hydroximic acid derivatives have the formula (I), in which the substituents have the following meanings: X stands for CH, CHO or NO; Y stands for O or NH; Z stands for O, S or NRa; Ra stands for hydrogen, alkyl, alkenyl or alkinyl; R1 st...
|
WO/1997/005105A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, AA and Y are as defined herein, inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor, and therefore are useful in the...
|
WO/1997/003966A1 |
Compounds selected from the group consisting of 2,N1-dihydroxy-3-isobutyl-N4-[2-methoxy-2-methyl-1-(pyridin-
2-yl-carbamoyl)-propyl]-succinamide, N1-(2-fluoro-2-methyl-1-methylcarbamoyl-propyl)-N4-hydroxy-2
-isobutyl-3-methoxy-succinamid...
|
WO/1997/002239A1 |
Compounds of formula (I), wherein R2 represents a group R6-A- wherein A represents a divalent straight or branched, saturated or unsaturated hydrocarbon chain of up to 12 C atoms and R6 represents hydrogen or an optionally substituted ar...
|
WO/1997/002237A1 |
The invention pertains to fluorobutenic acid oxime esters of formula (I) CF2=CX-CH2-CO-ON=CR1R2 in which: X stands for hydrogen or halogen; R1 and R2 independently of one another stand for hydrogen or (in each case optionally substituted...
|
WO/1997/001532A1 |
A ketonitrile derivative represented by general formula (1) or a salt thereof and an antibacterial agent and a drug containing the same, wherein R1 represents hydrogen or lower alkyl; R2, R3, R4 and R5 are the same or different and each ...
|
WO/1996/040662A2 |
Linker compounds for formation of stably-linked conjugates are disclosed. Such linker compounds are aminooxy-containing linker compounds useful in forming conjugates having stable oxime linkages. The stably-linked conjugates have utility...
|
WO/1996/040623A1 |
2-substituted 1,8-dihydroxy-9(10H)-antrhacenones of general formula (I), therapeutic compositions containing at least one 2-substituted 1,8-dihydroxy-9(10H)-anthracenone compound and methods of treating inflammatory conditions especially...
|
WO/1996/037464A1 |
Novel substituted amino acid derivatives are provided which inhibit platelet aggregation and which are useful in pharmaceutical compositions and methods of inhibiting platelet aggregation.
|
WO/1996/034851A1 |
The present invention provides a compound of formula (I), (II), (III) or (IV), processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and methods of using t...
|
WO/1996/034850A1 |
The present invention provides a compound of formula (I) processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and methods of using the compounds of the in...
|
WO/1996/033968A1 |
Novel compounds represented by general formula (I), stereoisomers thereof, pharmaceutically acceptable salts, and solvates thereof, processes for the preparation thereof, a matrix metalloproteinase inhibitor comprising as the active ingr...
|
WO/1996/033166A1 |
The present invention provides hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these compounds for the inhibition of matrix metalloproteinases, such as stromelysin, ...
|
WO/1996/033164A1 |
Hydroximic acid derivatives of general formula (I), wherein G is either G1 or G2 or G3 or G4 of the formula: R5OC=C(COOR4)-, R5ON=C(COOR4)-, R5ON=C(CONR6R7)-, R5OC=C(CONR6R7)-, X1, X2, X3 are H, halo, HO, mercapto, nitro, SCN, azido, CN,...
|
WO/1996/033160A1 |
The present invention provides dihalopropene compounds of general formula (I), wherein R1 is C1-C10 alkyl or the like; L is C(=O)NH or the like; R2, R3 and R4 are independently halogen or the like; R5, R6 and R7 are independently hydroge...
|
WO/1996/033161A1 |
Compounds of formula (I), wherein X is a -CO2H or -CONHOH group; R4 is a group -CHRxRy wherein Rx and Ry independently represent optionally substituted phenyl or monocyclic heteroaryl rings, which optionally may be linked covalently to e...
|
WO/1996/033176A1 |
The present invention provides novel hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these novel compounds for the inhibition of matrixmetalloproteinases, such as st...
|
WO/1996/033165A1 |
Compounds of formula (I), wherein X is a -CO2H or -CONHOH group; R4 is a group -CHRxRy wherein Rx and Ry independently represent optionally substituted phenyl or monocyclic heteroaryl rings, which optionally may be linked covalently to e...
|
WO/1996/031461A1 |
Phenoxyethylamine derivatives of general formula (I) having high affinity for the 5-HT1A receptor, methods for preparing same, pharmaceutical compositions containing said derivatives, and their use, in particular as gastric acid secretio...
|
WO/1996/030036A1 |
Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides, such as rhGH. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration, are pr...
|
WO/1996/030381A1 |
Amino amide derivatives of general formula (I), wherein R1 is hydrogen or C1-3-alkyl, optionally substituted with hydroxy, R2 is hydrogen, straight or branched C1-6-alkyl, or straight or branched C1-6-alkyl, mono-, di- or trisubstituted ...
|
WO/1996/026918A1 |
A method for the preparation of carboxylic and hydroxamic acid derivatives by cocondensation in a liquid organic medium of three reaction components, namely a carboxylic acid reaction component of formula (II), an imine reaction componen...
|
WO/1996/025398A1 |
The invention relates to novel substituted heterocyclic compounds, several processes for their production and their use as fungicides, and novel intermediate products, several processes for their production and their use as fungicides.
|
WO/1996/020918A1 |
The invention provides hydroxamic acid-containing compounds which are useful as inhibitors of matrix metalloproteases and which are effective in treating conditions associated with excess activity of these enzymes. In particular, the pre...
|
WO/1996/019442A1 |
A benzamidoxime derivative having an excellent bactericidal activity, being useful as an agrohorticultural bactericide, and represented by general formula (I) wherein R1 represents C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl, each of whi...
|
WO/1996/019441A1 |
A new and versatile route to N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobut
yl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxybutanedia
mide, desferrioxamine B (DFO) is described. N-Benzyloxy-1,5-diaminopentane is selectiv...
|
WO/1996/017838A1 |
There is described the use of a compound represented by general formulae (I), (II) or (III), for the inhibition of matrix metalloproteinases (MMP), wherein X1 is oxygen or sulfur, R1 is OH, SH, CH2OH, CH2SH or NHOH, R2 is a residue of 2 ...
|
WO/1996/016679A1 |
Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic acid chelator, for example DTPA ...
|
WO/1996/016931A1 |
Compounds of general formula (I), principally characterized in that R4 is a polyether group, are water soluble matrix metalloproteinase inhibitors.
|
WO/1996/016030A1 |
Iminooxymethylene anilides have the formula (I), in which the substituents and indices have the following meanings: R stands for hydrogen, optionally substituted alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, cycloalkinyl, alkylcarbo...
|
WO/1996/016027A1 |
Compounds of formula (I) and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as stromelysin, gelatinase, matrilysin and collagenase, and are useful in the treatment of mammals having disease-states alleviate...
|
WO/1996/016029A1 |
2-[4-biphenyl-oxymethylene]-anilides have the formula (I), in which the indices and substituents have the following meanings: R, R1, R2 stand for cyano, nitro, halogen, alkyl, alkyl halide, alkoxy, alkoxy halide, alkylthio, alkylthio hal...
|
WO/1996/013509A1 |
Fluorinated alkene compounds having structure (I) wherein Q is -(C=S)-R1, -(C=W)-R2, or -(P=W)R3R4; wherein W is O or S; and R1 to R4 are as defined in claim 1; are useful for controlling nematodes, insects, and acarids that prey on agri...
|
WO/1996/006822A1 |
The present invention relates to compounds of formula (I) wherein: A is an optionally substituted ring system as defined herein; B is an optionally substituted 5- or 6-membered heteroaryl ring system or optionally substituted phenyl; D i...
|
WO/1996/006074A1 |
Compounds of formula (I) principally characterised in that R4 is an optionally substituted C3-C8 cycloalkyl group or optionally substituted C4-C8 cycloalkenyl group are inhibitors of matrix metalloproteinases.
|
WO/1996/004253A1 |
This invention relates to novel processes for preparing the pharmaceutically active compound 5-(3-[(2S)-exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-
3,4,5,6-tetrahydropyrimidin-2(1H)-one and its corresponding 2R enantiomer and for p...
|
WO/1996/004239A1 |
New N-alkoxy-amidine derivatives having the formula (I) are disclosed, as well as a process for preparing the same and their use as pesticides. Also disclosed are new intermediate products and a process for preparing the same.
|
WO/1996/002518A1 |
Substituted cinnamic oxime derivatives (I) and hydroxamide derivatives (II) (formulae I and II) where R1 = halogen, NO2, CN, CF3; R2 = H, halogen; R3 = H, halogen, C1-C6 alkyl halide, C3-C6 alkenyl, C3-C6 alkinyl, hydroxy-C1-C4 alkyl; R4...
|
WO/1996/002497A1 |
The novel compounds of formula (I) (the meanings of A and R1 to R4 are given in the description) may be produced by conventional methods and therapeutically used as, for example, LTB4 antagonists.
|
WO/1995/035275A1 |
Compounds of general formula (II) wherein X is a hydroxamic or carboxylic acid group, Y is carbonyl or sulphonyl and R1 and R2 are as defined in the claims, are matrix metalloproteinase inhibitors.
|
WO/1995/035276A1 |
Compounds of general formula (II), wherein X is a hydroxamic or carboxylic acid group, Y is sulphonyl and R1 and R2 as defined in the claims are matrix metalloproteinase inhibitors.
|
WO/1995/033709A1 |
The invention provides hydroxylamine derivatives of formula (I) wherein A, R1, R2 and R3 have the significance given in the description, which are matrix metalloproteinase inhibitors and which also prevent TNF release. They are therefore...
|
WO/1995/032944A1 |
Compounds of general formula (I) wherein X is a -CO2H, -N(OH)CHO or -CONHOH group; R1 is hydrogen; (C1-C6)alkyl; (C2-C6)alkenyl; phenyl; substituted phenyl; phenyl(C1-C6)alkyl; substituted phenyl(C1-C6)alkyl; heterocyclyl; substituted he...
|
WO/1995/031977A1 |
The present invention provides the compound having structure (I), wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloa...
|
WO/1995/032184A1 |
Aminimide- and oxazolone-based molecules, and arrays thereof, having at least two structural diversity elements are made via systematic modular production. A combinatorial library of aminimide- and oxazolone-based molecules is made via s...
|
WO/1995/030644A1 |
Novel carbocyclic amides together with their salts, solvates and physiologically active derivatives which have a number of uses in medicine, in particular as central muscle relaxants, and in the treatment or prophylaxis of anxiety, infla...
|
WO/1995/030649A1 |
The invention relates to novel compounds of formula (I), wherein X means halogen; Z stands for an aromatic group, pyridinyl group or the like; and R represents an alkyl or phenylalkyl group or an -A-N(R1)R2 group, and in the latter R1 an...
|
WO/1995/029889A1 |
Compounds of formula (I) in which X is (a) or (b), n is 0, 1, 2, 3, 4 or 5, where if n is greater than 1, the radicals R2 are identical or different; o is 0, 1, 2, 3 or 4, where if o is greater than 1, the radicals R3 are identical or di...
|
WO/1995/024383A1 |
New oxime derivatives are disclosed, as well as several processes for preparing the same and their use as pesticides.
|
WO/1995/024382A1 |
There is disclosed a novel amino glycol derivatives of L-N6-(1-iminoethyl)lysine, pharmaceutical compositions containing these novel compounds, and to their use in therapy, in particular their use as nitric oxide synthase inhibitors.
|